[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643343":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":82,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Luspatercept group","EXPERIMENTAL","Luspatercept",[13],"Drug: Luspatercept",{"label":15,"type":16,"description":17,"interventionNames":18},"Epoetin group","ACTIVE_COMPARATOR","Epoetin",[19],"Drug: Epoetin",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Luspatercept is administered 1.0mg\u002Fkg subcutaneously every 3 weeks; If the hemoglobin level does not increase after two consecutive administrations, the dose will be adjusted to 1.3mg\u002Fkg. If the hemoglobin level returns to the normal range, Luspatercept will be given once before discontinuing the medication.",[9],null,{"type":22,"name":17,"description":27,"armGroupLabels":28,"otherNames":25},"Epoetin is administered 15000 IU subcutaneously every 3 weeks for 24 weeks",[15],[30],{"name":31,"affiliation":5,"role":32},"Qifa Liu","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Li Xuan","CONTACT","+86-020-61641613","356135708@qq.com",{"name":31,"role":36,"phone":40,"phoneExt":25,"email":41},"+86-020-62787883","liuqifa628@163.com",[43],{"facility":44,"status":25,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Department of Hematology, Nanfang Hospital, Southern Medical University","Guangzhou","Guangdong","510515","China","CN",{"type":51,"coordinates":52},"Point",[53,54],113.25,23.11667,{"lat":54,"lon":53},[57,58],{"name":31,"role":36,"phone":40,"phoneExt":25,"email":41},{"name":25,"role":36,"phone":25,"phoneExt":25,"email":41},{"type":60,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100643343","phase-2-luspatercept-vs-epoetin-in-treating-poor-erythroid-engraftment-for-hematological-malignancies-100643343",false,"NCT07636486","Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Inclusion Criteria:\n\n* 18-65 years\n* Hematologic malignancies\n* Poor erythroid engraftment after the first allo-HSCT\n* Complete remission post-transplantation\n* Eastern Cooperative Oncology Group performance status of 0-2\n* Epoetin-naive\n* Endogenous serum erythropoietin concentration \\\u003C500 U\u002FL\n\nExclusion Criteria:\n\n* Life expectancy shorter than 30 days post-transplantation\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)","ALL","18 Years","65 Years",{"count":72,"type":73},90,"ESTIMATED","INTERVENTIONAL",[76,77],"PHASE2","PHASE3","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.",[11,17,80,81],"Poor Erythroid Engraftment","Hematological Malignancies","NOT_YET_RECRUITING","2026-06-04",{"date":85,"type":86},"2026-06-09","ACTUAL",{"date":88,"type":73},"2026-06-15",{"date":90,"type":73},"2030-12-31",{"name":5,"class":6},1]